BioLabs LA Presents: Boehringer Ingelheim BI Academy & Networking Reception

Boehringer Ingelheim Academy

Our Grass Roots activities are centered around developing a personal relationship with the companies we work with. And our Academy sessions provide an informal opportunity for early-stage life-science companies to network with other bio-entrepreneurs as well as hear from Boehringer Ingelheim business development, scientific and commercial leaders and some of our partners and key opinion leaders.

Panel Topic

Boehringer Ingelheim's BI Academy brings together business development, scientific and commercial leaders, together with some of our partners and key opinion leaders to discuss timely topics of interest in an interactive setting. BI Academy is an informal opportunity for early-stage life-science companies to network with other bio-entrepreneurs as well our BI colleagues. In this session we will discuss two topics:

• How does a pharmaceutical company contribute to an ecosystem?

• How to do a deal with Boehringer Ingelheim

It is often argued that ecosystems require the essential ingredients of world class academic institutions, access to capital (especially venture capital), key support services like lawyers and accountants, and big pharma and biotech. But what exactly does pharma do for an ecosystem, and what can it do? At BI we have taken grass roots approach to supporting ecosystems by addressing the needs of burgeoning life-science companies and taking a longer view towards these early-stage companies. Come join this panel discussion to see how pharma increasingly play a much different role in ecosystems and to voice what you want to see pharma companies do.

Panel I: How does a pharmaceutical company contribute to an ecosystem?

Panelists:

• Cyrille Kuhn - North American Head of Research Beyond Borders
• Jennifer Landress - COO, Biocom
• Jen Dryer - Executive Director, USC Stevens Center for Innovation at University of Southern California
• Jasson Crockett - Manager, Economic Policy, City of Los Angeles
• Vasiliki Anest - Sr. Director, Business Development and Industry Relations, Keck School of Medicine, USC

Panel II: How to do a deal with Boehringer Ingelheim

Panelists:

• Kanad Das - Executive Director, BI Venture Fund
• Cyrille Kuhn - North American Head of Research Beyond Borders
• Scott DeWire - Global Head of Immuno-Oncology, BD&L

Agenda

3:00 pm - 4:00 pm

Arrival, registration & networking

4:00 pm – 4:45 pm

Panel I: How does a pharmaceutical company contribute to an ecosystem?

4:45 pm – 5:30 pm

Panel II: How to do a deal with BI

5:30 pm – 6:30 pm

Networking

Boehringer Ingelheim is one of the world's largest pharmaceutical companies, and the largest private one. Headquartered in Ingelheim, it operates globally with 146 affiliates and more than 47,700 employees. Unlike most large pharmaceutical companies, the company is private and fully owned by the Boehringer, Liebrecht and von Baumbach families. The company's key areas of interest are: respiratory diseases, metabolism, immunology, oncology and diseases of the central nervous system. Boehringer Ingelheim is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA).

BUILDING BETTER BIOTECHS

BioLabs are the premier co-working spaces for life science startups — unique places where you can test, develop and grow your game-changing ideas. As entrepreneurs and investors ourselves, we have first-hand experience with the pain-points biotech start-ups face. Our goal is to change how scientific entrepreneurs do business by building an ecosystem that empowers bioinnovators to grow quickly, while maximizing capital efficiency.

Enabling awesome - one bench at a time

The Lundquist Institute for Biomedical Innovation is a 501(c)3 independent non-profit biomedical research organization that was founded in 1952. The Institute has over more than 120 principal investigators and 400 researchers in total — MD’s, MD/PhD’s, and PhD’s — working on over 1,000 research studies. We are academically affiliated with the David Geffen School of Medicine at UCLA and work in partnership with the Harbor-UCLA Medical Center. Our research is funded by many sources including: grants from the NIH and other government entities, Industry and teaching contracts and royalties, as well as private donors and other non-profit foundations.

BY THE NUMBERS

• 100+ internationally recognized research groups
• 600 ongoing research projects
• 150 grants from federal sources (NIH and DoD) support our researchers
• 500+ peer-reviewed articles in prestigious medical and scientific journals annually
• 200 patents and 15 new filings annually
• 11 companies spun off in the past 10 years to bring The Lundquist Institute discoveries to the bedside

JUST THE FACTS

• The Lundquist Institute is one of the foremost independent, non-profit research institutes in the U.S.
• You have likely benefited at some point in your life from innovations by The Lundquist Institute.
• We developed the training for (and coined the term) "Paramedics"
• The profession of Nurse Practitioner had its beginning on our campus
• We have generated new paradigms, diagnostics, therapies, and devices, in use all over the world.
• We take on the challenge of devising treatments for debilitating and fatal rare inherited diseases.